Israni, Muskan
Nicholson, Bethany
Mahlaoui, Nizar
Obici, Laura
Rossi-Semerano, Linda
Lachmann, Helen
Hayward, Georgia
Avramovič, Mojca Zajc
Guffroy, Aurelien
Dalm, Virgil
Rimmer, Rachel
Solis, Leire
Villar, Carlotta
Gennery, Andrew R.
Skeffington, Stephanie
Nordin, Julia
Warnatz, Klaus
Korganow, Anne-Sophie
Antón, Jordi
Cattalini, Marco
Amin, Tania
Berg, Stephan
Soler-Palacin, Pere
Burns, Siobhan O.
Campbell, Mari
Wouters, C.
Meyts, I.
van der Werff ten Bosch, J. E.
Goffin, L.
Ogunjimi, B.
Gilliaux, O.
Kelecic, J.
Jelusic, M.
Fingerhutová, Š.
Sediva, A.
Herlin, T.
Seppänen Mikko, R. J.
Aalto, K.
Ritterbusch, H.
Insalaco, A.
Moschese, V.
Plebani, A.
Cimaz, R.
Canessa, C.
Dellepiane, R. M.
Carrabba, M.
Barzaghi, F.
van Laar, J. A. M.
Wulffraat, N. M.
Marques, L.
Carreras, C.
Sánchez-Manubens, J.
Alsina, L.
Seoane Reula, M. E.
Mendez-Echevarria, A.
Gonzales-Granado, L. I.
Santamaria, M.
Neth, O.
Ekwall, O.
Brodszki, O.
Hague, H.
Devlin, L. A.
Brogan, P.
Arkwright, P. D.
Riordan, A.
McCann, L.
McDermott, E.
Faust, S. N.
Carne, E.
,
Article History
Received: 7 March 2022
Accepted: 7 August 2022
First Online: 12 October 2022
Declarations
:
: All authors agreed to this publication.
: Consent to participate was requested in the email invitation sent to professionals which included information about what data would be collected and how data provided would be used.
: BN was contracted to work on this project by Royal Free Hospital and Great Ormond Street Hospital; SB<sup>1</sup> has received grant support from the European Union, National Institute of Health Research, UCLH and GOSH/ICH Biomedical Research Centers, and CSL Behring and personal fees or travel expenses from Immunodeficiency Canada/IAACI, CSL Behring, Baxalta US Inc, and Biotest; MC<sup>1</sup> has received grant support from the National Institute of Health Research, PIDUK, CSL Behring and the Royal Free Charity and personal fees or travel expenses from Biotest, BPL, CSL Behring, Grifols, HAEUK, Shire, and Takeda; LR-S has received consulting fees from Pfizer and AbbVie, and support for attending meetings or travel expenses from Novartis, Sobi, Medac, AbbVie, and Pfizer; ARG has received research funding from Mallinckrodt and JAZZ Pharmaceuticals; AG and ASK receive research funding from CSL Behring and Takeda; SB<sup>2</sup> has received payment or honoraria for speakers bureaus from Sobi and Novartis; PSP has received grant support from the European Union, Instituto Carlos III, Grifols, and CSL Behring and personal fees or travel expenses from CSL Behring, Takeda, and Grifols; JA has received grant support from the European Union, Insituto Carlos III, Fundación Daniel Bravo, research support from Novartis, Sobi, Novimmune, Roche, Pfizer, Lilly, AbbVie, and Amgen, and personal fees or travel expenses from Novartis, Sobi, Roche, Pfizer, Lilly, AbbVie, and Gebro; MC<sup>2</sup> has received speaking fees from Novartis Farma, AbbVie, Sobi, and Pfizer; KW is on the advisory boards for Shire Deutschland GmbH and LFB biomedicals, and has received grant support from BMS, honoraria for lectures, symposiums, and meetings from CSL Behring and Shire, and travel expenses from Shire; HL is the President-Elect for ISSAID, Council Member of the Nephrology section of the Royal Society of Medicine, and Vice-Chair of MHRA EAG; HL has received grant support for ImmunAID from EUH2020, consulting fees from Novartis, Sobi, and Roche, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis and Sobi, and support for attending meetings and/or travel from DADA2 patient society and Sobi; IM is the president of European Society for Immunodeficiencies, a board member of Astra Zeneca Foundation, and a senior clinical investigator at FWO Vlaanderen, IM has received grant support from CSL Behring Primary Immunodeficiencies Chair, European Research Council under the European Union’s Horizon 2020 research and innovation program, FWO Vlaanderen, VIB Grand Challenges Program, KU Leuven Onderzoeksraad, and the Jeffrey Modell Foundation, IM has received honoraria for lecturing by CSL Behring; JVDH has received consulting fees from Novartis and Sobi, and payment for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Sobi; LG is a participant on the Data Safety Monitoring board or Advisory Board for Novartis, and has received payment for presentations from Novartis, and support for attending meetings and/or travel expenses from AbbVie and Novartis; ŠF has received payment or honoraria for presentations and meeting/travel expenses from Sobi; AS has received payment or honoraria for presentations, lectures, speakers bureaus, educational events, or manuscript writing from Takeda, CSL Behring, and Octapharma; TH has received payment for lectures from Novartis, and support for attending meetings from Sobi; TRL is a participant on the advisory board for Sanofi-Pasteur, and has received support for attending meetings and/or travel from Takeda; VM is the president of the Vaccine Committee of the Italian Society of Pediatric Allergy and Immunology, and has received personal fees from Takeda and CSL Behring, and travel/meeting expenses from CSL Behring; JAMvL has received payment for expert testimony from Amgen and Sobi; NMW is the coordinator of ERN-RITA, and a participant in an investigator-initiated study on the effect of intranasal administration of palivizumab on respiratory syncytial virus-associated infection. NMW has received grant support from ZONMW and ReumaNederland, and consulting fees from Sanofi-Genzyme and UCB; FOR has received support for attending meetings and/or travel from Novartis; PČ has received support for attending meetings and/or travel from Takeda; CC is a pediatric representative on the Committee of primary Immunodeficiencies Hospital Universitario y Politecnico La Fe, and has received support for this manuscript from Hospital Universitario y Politecnico La Fe—Valencia, and support for attending meetings and/or travel expenses from CSL Behring; JS-M has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer, and meeting/travel expenses from AbbVie; LA has received consulting fees from CSL Behring, Grifols, Shire, and Takeda, honoraria for lectures from CSL Behring, Shire, and Takeda, and meeting/travel expenses from CSL Behring, Grifols, Shire, and Takeda; MERS participates on the Data Safety Monitoring Board or Advisory Board for Takeda has received meeting/travel expenses from CSL Behring and ALK, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Takeda and CSL Behring; LIG-G is a medical advisor for AEDIP and has received grant support from Fondo de Investigación Sanitaria, co-financed with FEDER funds; OE has received grant support from the Swedish Research Council; LAD has received funding to attend an educational event from CSL, and support to attend a speaker meeting for GPs from ALK; AJJW is a participant on the advisory board for Orchard Therapeutics; PB is a trustee of UK charity Societi, treasurer of International Society of Systemic Autoinflammatory Diseases, and participant on the NOVARTIS gene therapy advisory board, PB has received grant support from the European Union for an investigator-led clinical trial of Prednisolone in Kawasaki disease, consulting fees from Sobi and Novartis, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Sobi, Roche, and Novartis, and payment for expert testimony from KD Scotland; SS is the Chair of UKPIN, and has received grant support from CSL Behring, and consulting fees from Takeda and Novartis; SF is a participant on the advisory boards for AstraZeneca, Medimmune, Sanofi, Pfizer, Seqirus, Sandoz, Merck, and J&J, and was the chair of UK NICE Sepsis (2014–2016) and Lyme Disease (2016–2018) Guidelines, SF has received the NIHR Senior Investigator Award, grant support from Pfizer, Sanofi, GSK, J&J, Merck, AstraZeneca, and Valneva, and payment for symposiums from Pfizer. No other authors have competing interests.